Q BioMed Inc. Stock News

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the health

Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Str

Q BioMed Inc said its MAN-19 therapeutic, which it is developing with partner Mannin Research, is poised to start clinical trials in 2022. The MAN-19 therapeutic is a recombinant fusion protein and is

NEW YORK, Sept. 22, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatm

Q BioMed Inc said it has received a Notice of Allowance for the patent of its Uttroside B asset in South Korea, adding to the patents already secured in Canada and Japan for the liver cancer chemother

Q BioMed Inc. has recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing services and solutions to the nu

Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Str

Q BioMed Inc (OTCQB:QBIO) revealed that it has struck an exclusive license agreement with authorized Europe and Middle East distributor Clionix for the distribution and sales of the company's metastat

Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Str

NEW YORK, May 20, 2021 /PRNewswire/ --  Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has hired WSI PBG, LLC (WSI), a Michigan based firm specializing in c

Q BioMed Inc (OTCQB:QBIO) has unveiled its largest single investment so far, with Aedesius Holdings Ltd (AedesiusOne), a privately held global disruption aggregator, investing up to $30 million in th

Q BioMed Inc (OTCQB:QBIO) has released a letter to shareholders, bringing them up to speed on the developments of its technology partner, Mannin Research, and its work to treat the coronavirus (COVID-

NEW YORK, April 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Rese

Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Str

10.25am: Proactive North America headlines: Tartisan Nickel Corp (CSE:TN) (OTCMKTS:TTSRF) (FRA:8TA) poised for geophysical survey at flagship Kenbridge nickel-copper-cobalt project Psyched Wellness Lt